Novel 4-aminoquinoline analogs targeting the HIF-1α signaling pathway

Future Med Chem. 2023 Sep;15(17):1569-1582. doi: 10.4155/fmc-2023-0169. Epub 2023 Sep 20.

Abstract

Background: The aminoquinoline core exhibits versatile pharmacological properties, particularly in the area of anticancer activity. This study was designed to investigate the potential of the 4-aminoquinoline scaffold in the development of anticancer agents by targeting the HIF-1α signaling pathway. Methodology: The authors synthesized multiple derivatives of 4-aminoquinoline containing heterocyclic rings by a microwave reactor and assessed the cytotoxicity and inhibitory effects of these derivatives on the HIF-1α signaling pathway. Conclusion: Compound 3s was identified as the most promising HIF-1α inhibitor due to its exceptional antiproliferative effects, with IC50 values of 0.6 and 53.3 nM observed in MiaPaCa-2 and MDA-MB-231 cells, respectively. Furthermore, compound 3s was found to inhibit HIF-1α expression by decreasing the level of HIF-1α mRNA.

Keywords: 4-aminoquinoline; anticancer; hypoxia-inducible factor-1α.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoquinolines / pharmacology
  • Antineoplastic Agents* / pharmacology
  • Cell Line, Tumor
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • RNA, Messenger
  • Signal Transduction*

Substances

  • 4-aminoquinoline
  • Antineoplastic Agents
  • Aminoquinolines
  • RNA, Messenger
  • Hypoxia-Inducible Factor 1, alpha Subunit